← Browse by Condition
Medical Condition
autosomal dominant polycystic kidney disease
Total Trials
2
Recruiting Now
2
Trial Phases
Various
Chronic kidney disease (CKD) and end-stage renal disease trials have been revitalized by SGLT2 inhibitors, which reduce CKD progression in both diabetic and non-diabetic patients through hemodynamic and anti-inflammatory mechanisms beyond glucose lowering. Targeting residual risk after SGLT2 and RAAS inhibition is the current frontier, with mineralocorticoid receptor antagonists (finerenone) already approved.
Active trials evaluate sparsentan (dual endothelin-angiotensin antagonist) in IgAN, iptacopan for complement-mediated nephropathy, bardoxolone for Alport syndrome, and dicarba-based gene therapy for FSGS. Urine biomarkers (UACR, NGAL) and eGFR slope are standard endpoints, with surrogate-to-hard endpoint validation ongoing.
Frequently Asked Questions — autosomal dominant polycystic kidney disease Clinical Trials
How many clinical trials are currently recruiting for autosomal dominant polycystic kidney disease?
ClinicalMetric currently tracks 2 actively recruiting clinical trials for autosomal dominant polycystic kidney disease, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 2. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for autosomal dominant polycystic kidney disease?
autosomal dominant polycystic kidney disease research spans multiple clinical trial phases. Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a autosomal dominant polycystic kidney disease clinical trial?
Eligibility criteria for autosomal dominant polycystic kidney disease trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Top Sponsors
1 trial
1 trial
Recruiting Clinical Trials
NCT04344769
Recruiting
Characterization of the Nrf2 Response in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Enrollment
40 pts
Location
United States
Sponsor
Mayo Clinic
NCT06065852
Recruiting
National Registry of Rare Kidney Diseases
Enrollment
35,000 pts
Location
United Kingdom
Sponsor
UK Kidney Association
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology